Comparing Pfizer Stock and Eli Lilly Stock



Stock performance

As we discussed earlier, Pfizer (PFE) stock has risen ~5.8% to date in September, and it closed at $43.93 on September 24. Eli Lilly and Company (LLY) stock has fallen a marginal ~0.1% so far in September, and its closing price was $105.59 on September 24.

The above chart compares the normalized stock prices of Pfizer and Eli Lilly in September. Pfizer’s market cap is ~$257.2 billion, while Eli Lilly’s market cap is ~$105.3 billion as of September 25.

Article continues below advertisement

Revenue and EPS performance 

Eli Lilly reported adjusted EPS of $1.50 on revenue of ~$6.3 billion in the second quarter, a 9.1% year-over-year rise in revenue compared to its adjusted EPS of $1.11 on revenue of ~$5.8 billion in the second quarter of 2017.

Technical indicators

Eli Lilly stock is currently trading ~0.2% below its 20-day simple moving average. The stock is also trading ~4.2% higher than its 50-day simple moving average and ~21.4% higher than its 200-day simple moving average as of September 24, showing that its stock price could fall further in the near future.

Analysts’ recommendations

Analysts have a 12-month target price of $98.3 on Eli Lilly stock, which reflects a potential ~6.9% fall from its price of $105.59 as of September 24.

The SPDR S&P Pharmaceuticals ETF (XPH) holds 5.0% of its total investments in Eli Lilly, 4.7% in Pfizer, 4.5% in Johnson & Johnson (JNJ), and 4.5% in Merck & Co. (MRK).


More From Market Realist